Printer Friendly

ThromboScience Announces New Cardiovascular Risk Factor.

WOODSIDE, Calif. -- ThromboScience(TM), LLC, a provider of blood tests that determine cardiovascular risk, announced that it has measured a new risk factor that strongly predicts complications from heart disease in patients who have had coronary artery stenting.

"After more than ten years of basic research and clinical studies with hundreds of patients, we are pleased to make available the ThromboProfile," said Cora Yang, President. "ThromboScience offers the most comprehensive test to measure platelet reactivity and coagulation as pivotal risk factors for thrombotic events. Our new test, the ThromboProfile(TM), measures platelet reactivity and the tendency for blood clotting in a patient, the most common events that occur before a heart attack or stroke."

"The ThromboProfile is a powerful predictor of thrombotic events because it measures platelet reactivity and the tendency for blood clotting in addition to assessing traditional factors such as cholesterol, inflammation markers and LDL particle size," continued Yang. "Many patients have high levels of 'bad' LDL cholesterol, but never have a heart attack. The ThromboProfile is the only test which focuses on the critical and final pathways that directly lead to a heart attack."

"The mission of ThromboScience is to save lives by the early detection and diagnosis of thrombotic risk. Our technology assesses not only the risk of clotting, but also whether or not a patient is responsive to anti-platelet therapies including aspirin," said Yang. "With the founding of ThromboScience, we are embarking on a journey to make this new technology widespread, and we believe the impact on health care will be profound."

About ThromboScience, LLC

ThromboScience, based in Woodside, California, licenses the ThromboProfile, a new technology which combines traditional testing for heart disease with assessment of platelet function and coagulation in each patient, resulting in tailored therapy. For more information, please visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 22, 2005
Previous Article:Infodata Announces Restatement of Prior Period Financial Results.
Next Article:U.S. Premiere of ``Miss Congeniality 2: Armed and Fabulous'' Wednesday, March 23.

Related Articles
Air pollution is a serious cardiovascular risk.
A systematic approach to managing hypertension and the metabolic syndrome in primary care.
Predictive power of cardiovascular risk factors for detecting peripheral vascular disease.
Clinical use of C-reactive protein for cardiovascular disease.
The role of inflammation in diabetes and its complications.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters